Search for other papers by Xu Han in
Google Scholar
PubMed
Search for other papers by Xuefeng Xu in
Google Scholar
PubMed
Search for other papers by Hongyun Ma in
Google Scholar
PubMed
Search for other papers by Yuan Ji in
Google Scholar
PubMed
Search for other papers by Dansong Wang in
Google Scholar
PubMed
Search for other papers by Tiantao Kuang in
Google Scholar
PubMed
Search for other papers by Wenchuan Wu in
Google Scholar
PubMed
Search for other papers by Bin Song in
Google Scholar
PubMed
Search for other papers by Gang Li in
Google Scholar
PubMed
Search for other papers by Gang Jin in
Google Scholar
PubMed
Search for other papers by Wenhui Lou in
Google Scholar
PubMed
oligometastases have only a few metastatic spot. The median number of metastatic lymph-node was 1 (mean ( s.d. ) number, 1.2 (1.3); range, 0–7). Comparison of clinicopathologic characteristics between WD-pNETs G3 and PD-pNECs G3 A comparison of
Search for other papers by H A Booij in
Google Scholar
PubMed
Search for other papers by W D C Gaykema in
Google Scholar
PubMed
Search for other papers by K A J Kuijpers in
Google Scholar
PubMed
Search for other papers by M J M Pouwels in
Google Scholar
PubMed
Search for other papers by H M den Hertog in
Google Scholar
PubMed
injury due to stroke as well. PD and stroke Literature on the prevalence of PD in stroke is scarce, especially for the subacute and chronic phase. The most commonly found endocrine disturbance is growth hormone deficiency (GHD) ( Table 1 ). This
Search for other papers by Bliss Anderson in
Google Scholar
PubMed
Search for other papers by Daniel L Morganstein in
Google Scholar
PubMed
death-1 (anti-PD-1) or its ligand PD-L1 (anti-PD-L1) to potentiate anti-tumour immune responses. Such is their success, they have now become first-line therapy for metastatic melanoma, non-small cell lung cancer and renal cell carcinoma ( 3 ). They are
Search for other papers by Sanjeet Kumar Jaiswal in
Google Scholar
PubMed
Search for other papers by Vijaya Sarathi in
Google Scholar
PubMed
Search for other papers by Saba Samad Memon in
Google Scholar
PubMed
Search for other papers by Robin Garg in
Google Scholar
PubMed
Search for other papers by Gaurav Malhotra in
Google Scholar
PubMed
Search for other papers by Priyanka Verma in
Google Scholar
PubMed
Search for other papers by Ravikumar Shah in
Google Scholar
PubMed
Search for other papers by Manjeet Kaur Sehemby in
Google Scholar
PubMed
Search for other papers by Virendra A Patil in
Google Scholar
PubMed
Search for other papers by Swati Jadhav in
Google Scholar
PubMed
Search for other papers by Anurag Ranjan Lila in
Google Scholar
PubMed
Search for other papers by Nalini S Shah in
Google Scholar
PubMed
Search for other papers by Tushar R Bandgar in
Google Scholar
PubMed
performed to identify predictors of response to PRRT. Kappa coefficient was calculated to compare the agreement between RECIST 1.1 and change in SUV max of <15% for diagnosing PD and CD. P -value < 0.05 was considered as statistically significant
Search for other papers by Joana Simões-Pereira in
Google Scholar
PubMed
Search for other papers by Daniel Macedo in
Google Scholar
PubMed
Search for other papers by Maria João Bugalho in
Google Scholar
PubMed
. Follow-up since CNS-M1 detection (months) Status at last follow-up 1 PTC F 78 Single 3 No Complete WBR SD 37 Alive 2 PTC F 70 Multiple 0 Yes – WBR PD 2 Alive 3 PTC F 52
Faculté de Médecine Lyon Est, Université Lyon 1, Lyon, France
INSERM U1052; CNRS UMR5286; Cancer Research Centre of Lyon, Lyon, France
Search for other papers by Hélène Lasolle in
Google Scholar
PubMed
UFR Sciences médicales, Université de Bordeaux, Bordeaux, France
Search for other papers by Amandine Ferriere in
Google Scholar
PubMed
INSERM U1052; CNRS UMR5286; Cancer Research Centre of Lyon, Lyon, France
Centre de Pathologie et de Neuropathologie Est, Groupement Hospitalier Est, Hospices Civils de Lyon, Bron, France
Search for other papers by Alexandre Vasiljevic in
Google Scholar
PubMed
Service d’anatomo-pathologie, Hopital Pellegrin, CHU de Bordeaux, Bordeaux, France
Search for other papers by Sandrine Eimer in
Google Scholar
PubMed
Search for other papers by Marie-Laure Nunes in
Google Scholar
PubMed
UFR Sciences médicales, Université de Bordeaux, Bordeaux, France
Search for other papers by Antoine Tabarin in
Google Scholar
PubMed
/L) HbA1c (%) Glucose tolerance Treatment modifications FBG (g/L) HbA1c (%) Treatment modification 1 0.99 5.6 NGT 1.15 5.9 PD 6.1 2 1.19 7.2 TD Met + dpp4 1.08 8.4 TD insulin 4/d Stop
Search for other papers by Chanyang Kim in
Google Scholar
PubMed
Search for other papers by Seungjoon Park in
Google Scholar
PubMed
Introduction Parkinson’s disease (PD) is the second most common neurodegenerative disorder after Alzheimer’s disease. PD affects 1% of the population worldwide after the age of 65 years ( 1 ). The disease is characterized by a progressive
Search for other papers by Deborah Cosentini in
Google Scholar
PubMed
Search for other papers by Salvatore Grisanti in
Google Scholar
PubMed
Search for other papers by Alberto Dalla Volta in
Google Scholar
PubMed
Search for other papers by Marta Laganà in
Google Scholar
PubMed
Search for other papers by Chiara Fiorentini in
Google Scholar
PubMed
Search for other papers by Paola Perotti in
Google Scholar
PubMed
Search for other papers by Sandra Sigala in
Google Scholar
PubMed
Search for other papers by Alfredo Berruti in
Google Scholar
PubMed
-lymphocyte antigen 4 (CTLA-4), programmed death 1 (PD-1) and programmed death ligand 1 (PD-L1), are important therapeutic breakthroughs in medical oncology ( 5 ). These drugs have demonstrated to be efficacious (and obtained the US Food and Drug Administration – FDA
Search for other papers by M Axelstad in
Google Scholar
PubMed
Search for other papers by U Hass in
Google Scholar
PubMed
Search for other papers by M Scholze in
Google Scholar
PubMed
Search for other papers by S Christiansen in
Google Scholar
PubMed
Search for other papers by A Kortenkamp in
Google Scholar
PubMed
Search for other papers by J Boberg in
Google Scholar
PubMed
detectable was designated as gestation day (GD) 1 and independently of actual day of delivery, the expected day of delivery, GD 23 was designated as pup day (PD) 1. Thereby, the age of the pups related to the time of conception, but was rather similar to
Search for other papers by Sandeep Kumar Parvathareddy in
Google Scholar
PubMed
Search for other papers by Abdul K Siraj in
Google Scholar
PubMed
Search for other papers by Zeeshan Qadri in
Google Scholar
PubMed
Search for other papers by Saeeda O Ahmed in
Google Scholar
PubMed
Search for other papers by Felisa DeVera in
Google Scholar
PubMed
Search for other papers by Saif Al-Sobhi in
Google Scholar
PubMed
Search for other papers by Fouad Al-Dayel in
Google Scholar
PubMed
Search for other papers by Khawla S Al-Kuraya in
Google Scholar
PubMed
.6 Absent 613 44.6 Unknown 26 1.8 TERT mutation Present 181 12.9 Absent 1124 79.9 Unknown 102 7.2 PD-L1 IHC Positive 435 32.7 Negative 896 67.3 Initial surgery